Ovarian Cancer Retrospective European (O'CaRE) study: first-line outcomes by number of risk factors for progression.

Autor: Krell J; Institute of Reproductive and Developmental Biology, Imperial College London, London, W12 0HS, UK., Shaw D; The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, L7 8YA, UK., McGrane J; Sunrise Oncology Centre, Royal Cornwall Hospitals NHS Trust, Cornwall, TR1 3LJ, UK., Hartkopf A; Department of Women's Health, Universitätsklinikum Tübingen, Tübingen, 72076, Germany., Herrero A; Department of Medical Oncology, Hospital Universitario Miguel Servet, Zaragoza, 50009, Spain., Yeoh C; Queen Alexandra Hospital, Portsmouth, PO6 3LY, UK., Masvidal M; Medical Oncology Department, Hospital Universitari Sant Joan de Reus, Tarragona, 43204, Spain., Raspagliesi F; Gynecologic Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, 20133, Italy., York W; GSK, Medical & Market Access Oncology Statistics, Philadelphia, PA 19426, USA., Schilder JM; GSK, Philadelphia, PA 19426, USA., Mascialino B; GSK, Verona, 37135, Italy., McDermott E; GSK, Stevenage, SG1 2NY, UK., Kalilani L; GSK, Research Triangle, Durham, NC 27701, USA., Hanker L; Department of Gynecology & Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, 23538, Germany.; Department of Gynecology & Obstetrics, University Hospital Münster, Germany.
Jazyk: angličtina
Zdroj: Future oncology (London, England) [Future Oncol] 2024 Oct 24, pp. 1-11. Date of Electronic Publication: 2024 Oct 24.
DOI: 10.1080/14796694.2024.2402217
Abstrakt: Aim: The Ovarian Cancer Retrospective European (O'CaRE) study assessed the cumulative impact of high-risk factors on progression-free survival (PFS) and overall survival (OS) following first-line treatment in patients diagnosed with advanced ovarian cancer. Patients & methods: Medical records were collected from five European countries (2014 and 2015). Patients were grouped by number of high-risk factors: stage IV diagnosis, no known BRCA mutation , interval debulking surgery or no surgery, or visible residual disease. Results: Our analysis included 405 patients grouped based on having one (20.4%); two (32.3%); three (33.7%) or four (11.9%) high-risk factors. Increasing cumulative numbers of high-risk factors were associated with numerically shorter PFS and OS. Conclusion: Risk profiles should be carefully considered when planning clinical care.
Databáze: MEDLINE
Externí odkaz: